Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Protein kinase C-α (PKCα) modulates cell apoptosis by stimulating nuclear translocation of NF-kappa-B p65 in urothelial cell carcinoma of the bladder

Authors: Jin Zheng, Chuize Kong, Xiaoxi Yang, Xiaolu Cui, Xuyong Lin, Zhe Zhang

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The protein kinase C (PKC) family comprises central regulators of multiple signal transduction processes and is involved in the progression of many cancers. Nuclear factor Kappa-B (NF-κB) is constitutively expressed in cancer tissues and stimulates the transcription of various tumor-related genes. The present study aims to investigate the clinical significance of PKCα and NF-κB p65 in bladder cancer tissues and the mechanism underlying PKCα induction of bladder cancer cell apoptotic resistance through stimulation of p65 nuclear translocation.

Methods

Expression of PKCα and NF-κB subunit p65 was detected in seven bladder cancer cell lines by western blot and in 30 bladder cancer tissue specimens by immunostaining. Immunofluorescence was performed to evaluate p65 nuclear translocation induced by Phorbol 12-myristate 13-acetate (PMA). PKCα/β selective inhibitor Gö6976, PKC pan-inhibitor sotrastaurin, and the PKC siRNA were employed to conduct PKC inhibition/knockdown in bladder cancer cells. Luciferase reporter assays were performed to measure the activity of NF-κB. Flow cytometry and TUNEL analysis were used to assess cell apoptosis.

Results

Expression of PKCα and NF-κB was found to positively correlate with tumor progression in 30 tumor tissue specimens. Furthermore, a Pearson’s correlation coefficient analysis revealed a positive correlation between PKCα and NF-κB expression. Among the PKC inhibitors, the PKCα/β selective inhibitor Gö6976 yielded the most significant block of PKCα and NF-κB activation by PMA. Knockdown of NF-κB p65 remarkably induced cell apoptosis, but PMA restored p65 expression and significantly suppressed cell apoptosis that was otherwise induced by the p65 knockdown alone.

Conclusion

Our study showed that PKCα modulated cell resistance to apoptosis by stimulating NF-κB activation and thus promoted the tumorigenesis of bladder cancer.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Pang C, Guan Y, Li H, Chen W, Zhu G. Urologic cancer in China. Jpn J Clin Oncol. 2016;46(6):497–501.CrossRefPubMed Pang C, Guan Y, Li H, Chen W, Zhu G. Urologic cancer in China. Jpn J Clin Oncol. 2016;46(6):497–501.CrossRefPubMed
3.
go back to reference Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
4.
go back to reference Klotz L, Brausi MA. World urologic oncology federation bladder cancer prevention program: a global initiative. Urol Oncol. 2015;33(1):25–9.CrossRefPubMed Klotz L, Brausi MA. World urologic oncology federation bladder cancer prevention program: a global initiative. Urol Oncol. 2015;33(1):25–9.CrossRefPubMed
5.
go back to reference Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617–25.CrossRefPubMed Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617–25.CrossRefPubMed
6.
go back to reference Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther. 1993;59(3):257–80.CrossRefPubMed Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther. 1993;59(3):257–80.CrossRefPubMed
7.
go back to reference Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988;334(6184):661–5.CrossRefPubMed Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988;334(6184):661–5.CrossRefPubMed
8.
go back to reference Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007;7(4):281–94.CrossRefPubMed Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007;7(4):281–94.CrossRefPubMed
9.
go back to reference Varga A, Czifra G, Tállai B, et al. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol. 2004;46(4):462–5.CrossRefPubMed Varga A, Czifra G, Tállai B, et al. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol. 2004;46(4):462–5.CrossRefPubMed
10.
go back to reference Koivunen J, Aaltonen V, Koskela S, Lehenkari P, Laato M, Peltonen J. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004;64(16):5693–701.CrossRefPubMed Koivunen J, Aaltonen V, Koskela S, Lehenkari P, Laato M, Peltonen J. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004;64(16):5693–701.CrossRefPubMed
11.
go back to reference Yokoyama Y, Ito T, Hanson V, et al. PMA-induced reduction in invasiveness is associated with hyperphosphorylation of MARCKS and talin in invasive bladder cancer cells. Int J Cancer. 1998;75(5):774–9.CrossRefPubMed Yokoyama Y, Ito T, Hanson V, et al. PMA-induced reduction in invasiveness is associated with hyperphosphorylation of MARCKS and talin in invasive bladder cancer cells. Int J Cancer. 1998;75(5):774–9.CrossRefPubMed
12.
go back to reference Kong C, Zhu Y, Liu D, et al. Role of protein kinase C-alpha in superficial bladder carcinoma recurrence. Urology. 2005;65(6):1228–32.CrossRefPubMed Kong C, Zhu Y, Liu D, et al. Role of protein kinase C-alpha in superficial bladder carcinoma recurrence. Urology. 2005;65(6):1228–32.CrossRefPubMed
14.
go back to reference Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol. 1994;47(1):145–9.CrossRefPubMed Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol. 1994;47(1):145–9.CrossRefPubMed
17.
go back to reference Whiteside ST, Israel A. I kappa B proteins: structure, function and regulation. Semin Cancer Biol. 1997;8(2):75–82.CrossRefPubMed Whiteside ST, Israel A. I kappa B proteins: structure, function and regulation. Semin Cancer Biol. 1997;8(2):75–82.CrossRefPubMed
18.
go back to reference Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6853–66.CrossRefPubMed Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6853–66.CrossRefPubMed
20.
go back to reference Sliva D, English D, Lyons D, Lloyd FP. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun. 2002;290(1):552–7.CrossRefPubMed Sliva D, English D, Lyons D, Lloyd FP. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun. 2002;290(1):552–7.CrossRefPubMed
21.
go back to reference Shin Y, Yoon SH, Choe EY, et al. PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. Exp Mol Med. 2007;39(1):97–105.CrossRefPubMed Shin Y, Yoon SH, Choe EY, et al. PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. Exp Mol Med. 2007;39(1):97–105.CrossRefPubMed
22.
go back to reference Mukherjee N, Houston TJ, Cardenas E, Ghosh R. To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded. Carcinogenesis. 2015;36(3):299–306.CrossRefPubMed Mukherjee N, Houston TJ, Cardenas E, Ghosh R. To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded. Carcinogenesis. 2015;36(3):299–306.CrossRefPubMed
23.
go back to reference Du HF, Ou LP, Yang X, et al. A new PKCα/β/TBX3/E-cadherin pathway is involved in PLCε-regulated invasion and migration in human bladder cancer cells. Cell Signal. 2014;26(3):580–93.CrossRefPubMed Du HF, Ou LP, Yang X, et al. A new PKCα/β/TBX3/E-cadherin pathway is involved in PLCε-regulated invasion and migration in human bladder cancer cells. Cell Signal. 2014;26(3):580–93.CrossRefPubMed
24.
25.
go back to reference Jiang Z, Kong C, Zhang Z, Zhu Y, Zhang Y, Chen X. Reduction of protein kinase C α (PKC-α) promote apoptosis via down-regulation of Dicer in bladder cancer. J Cell Mol Med. 2015;19(5):1085–93.CrossRefPubMedPubMedCentral Jiang Z, Kong C, Zhang Z, Zhu Y, Zhang Y, Chen X. Reduction of protein kinase C α (PKC-α) promote apoptosis via down-regulation of Dicer in bladder cancer. J Cell Mol Med. 2015;19(5):1085–93.CrossRefPubMedPubMedCentral
26.
go back to reference Martiny-Baron G, Kazanietz MG, Mischak H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem. 1993;268(13):9194–7.PubMed Martiny-Baron G, Kazanietz MG, Mischak H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem. 1993;268(13):9194–7.PubMed
Metadata
Title
Protein kinase C-α (PKCα) modulates cell apoptosis by stimulating nuclear translocation of NF-kappa-B p65 in urothelial cell carcinoma of the bladder
Authors
Jin Zheng
Chuize Kong
Xiaoxi Yang
Xiaolu Cui
Xuyong Lin
Zhe Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3401-7

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine